Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters.
Several studies have demonstrated that low levels of serum adiponectin are present in obesity, insulin resistance, hypertension and hyperlipidemias. The aim of our study was to determine whether serum adiponectin level is different between patients with polycystic ovarian syndrome (PCOS) and control subjects. We also investigated relationships between various cardiovascular risk factors, levels of serum adiponectin and other hormones, such as androstendione, testosterone, estradiol, DHEAS, sex hormone binding globulin (SHBG), and leptin. We also analysed the correlation between serum adiponectin and free androgen index. Ninety-one women with clinical diagnosed PCOS and 53 healthy control subjects, carefully matched by body mass index (BMI) and age, were enrolled in the study. The fasting blood samples were obtained and all participants underwent an oral 75 g glucose tolerance test. The prevalences of impaired glucose tolerance (IGT), hypertension and hypertriglyceridemia were higher in the PCOS group. PCOS women had increased androgen concentrations and higher free androgen index and decreased level of serum SHBG. Lower serum adiponectin concentrations were observed among cases than in controls (median 13.7 microg/ml vs 17.8 microg/ml, p<0.001) despite being matched by BMI. In the PCOS group adiponectin levels correlated significantly with: BMI (r=-0.32, p=0.002), waist circumference (r=-0.32, p=0.003), waist-to-hip ratio (WHR, r=-0.38, p=0.001), triglycerides (r=-0.31, p=0.007), SHBG (r=0.30, p=0.003) and free androgen index (r=-0.29, p=0.02). In contrast, the adiponectin level does not appear to be related to total testosterone, DHEAS and leptin levels. The adiponectin and SHBG levels were found to be decreased in PCOS women with IGT compared to PCOS women with normal glucose tolerance, but after adjustment by BMI or WHR, the differences were no longer statistically significant. To exclude a possible confounding effect due to a higher prevalence of IGT in the PCOS group, this comparison was repeated for the subgroup of 58 PCOS women and 48 control women after excluding those with IGT. Neither adiponectin nor SHBG were significantly different between those subgroups. Multiple regression analysis revealed that serum adiponectin concentrations were best predicted by WHR, free androgen index and presence of IGT when all patients were considered. In PCOS subjects, the only independent predictor of adiponectin concentrations was glucose tolerance status.


CONCLUSIONS
Lower adiponectin levels were observed in PCOS group than in control women, and these differences were probably due to higher prevalence of IGT in these cases.
Sieminska
L
L
Department of Pathophysiology and Endocrinology, Silesian Medical University, Zabrze, Poland. siem@pik-net.pl
Marek
B
B
Kos-Kudla
B
B
Niedziolka
D
D
Kajdaniuk
D
D
Nowak
M
M
Glogowska-Szelag
J
J
D052242:Adiponectin; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000209:etiology; D016022:Case-Control Studies; D003094:Collagen; D015922:Complement C1q; D005260:Female; D005951:Glucose Tolerance Test; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000503:physiopathology*; D012044:Regression Analysis; D012307:Risk Factors; D049629:Waist-Hip Ratio
D052242:Adiponectin; D001786:Blood Glucose; D012739:Gonadal Steroid Hormones; D036341:Intercellular Signaling Peptides and Proteins; D015922:Complement C1q; D003094:Collagen
Eur J Endocrinol. 2002 Aug;147(2):173-80
12153737
Lancet. 2003 Jan 18;361(9353):226-8
12547549
Circulation. 2003 Oct 7;108(14):1688-93
12975257
J Clin Endocrinol Metab. 1999 Jun;84(6):1897-9
10372683
J Clin Invest. 2001 Dec;108(12):1875-81
11748271
Metabolism. 2002 Feb;51(2):235-7
11833054
J Clin Endocrinol Metab. 2003 Apr;88(4):1528-33
12679434
Diabetes. 2002 Oct;51(10 ):2968-74
12351435
J Clin Endocrinol Metab. 1999 Jan;84(1):165-9
9920077
Am J Physiol. 1998 Jun;274(6 Pt 1):C1645-52
9611130
Clin Endocrinol (Oxf). 1993 Jul;39(1):1-16
8348699
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2005-10
11172066
Am J Hypertens. 2003 Jan;16(1):72-5
12517687
J Clin Endocrinol Metab. 2001 May;86(5):1930-5
11344187
Circulation. 1999 Dec 21-28;100(25):2473-6
10604883
Nat Med. 2001 Aug;7(8):941-6
11479627
Acta Obstet Gynecol Scand. 1992 Dec;71(8):599-604
1336918
Hum Reprod. 2003 May;18(5):980-4
12721172
J Clin Endocrinol Metab. 1991 Jan;72(1):83-9
1898744
Hum Reprod. 2000 Apr;15(4):785-9
10739820
Diabetes. 2003 Feb;52(2):239-43
12540592
J Clin Endocrinol Metab. 2002 Dec;87(12):5821-5
12466392
Clin Endocrinol (Oxf). 2000 May;52(5):595-600
10792339
J Hum Hypertens. 1997 Aug;11(8):523-6
9322834
J Clin Endocrinol Metab. 2003 Jun;88(6):2619-23
12788865
J Biol Chem. 2002 Jul 19;277(29):25863-6
12032136
Clin Endocrinol (Oxf). 2003 May;58(5):562-71
12699437
Diabetes. 2002 Sep;51(9):2734-41
12196466
Semin Reprod Endocrinol. 1998;16(2):121-8
9711677